Autolus Therapeutics (NASDAQ:AUTL) Reaches New 52-Week Low - What's Next?

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) shares reached a new 52-week low during trading on Wednesday . The company traded as low as $2.07 and last traded at $2.25, with a volume of 1651083 shares traded. The stock had previously closed at $2.18.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on AUTL. Needham & Company LLC reaffirmed a "buy" rating and set a $10.00 target price on shares of Autolus Therapeutics in a research note on Thursday, December 5th. Redburn Atlantic upgraded shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price objective for the company in a research report on Friday, November 15th. Finally, The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $10.40.

Autolus Therapeutics Stock Up 3.2 %

The company has a market capitalization of $598.71 million, a price-to-earnings ratio of -1.86 and a beta of 1.99. The business has a 50-day moving average price of $3.28 and a 200-day moving average price of $3.74.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the previous year, the business posted ($0.26) earnings per share. As a group, sell-side analysts predict that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Several hedge funds have recently made changes to their positions in AUTL. Wellington Management Group LLP boosted its position in Autolus Therapeutics by 35.4% during the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company's stock worth $87,919,000 after acquiring an additional 6,330,392 shares during the period. FMR LLC lifted its position in shares of Autolus Therapeutics by 44.6% in the third quarter. FMR LLC now owns 17,773,873 shares of the company's stock worth $64,519,000 after purchasing an additional 5,478,706 shares in the last quarter. Great Point Partners LLC boosted its holdings in shares of Autolus Therapeutics by 195.0% during the second quarter. Great Point Partners LLC now owns 3,441,667 shares of the company's stock worth $11,977,000 after purchasing an additional 2,275,000 shares during the period. Armistice Capital LLC grew its position in Autolus Therapeutics by 33.8% during the second quarter. Armistice Capital LLC now owns 6,250,000 shares of the company's stock valued at $21,750,000 after purchasing an additional 1,578,000 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in Autolus Therapeutics by 74.5% during the second quarter. Bank of New York Mellon Corp now owns 2,531,688 shares of the company's stock valued at $8,810,000 after purchasing an additional 1,080,897 shares in the last quarter. Hedge funds and other institutional investors own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.